|1.||Majima, Masataka: 1 article (01/2014)|
|2.||Katori, Makoto: 1 article (01/2014)|
|3.||Horstick, Georg: 1 article (09/2012)|
|4.||Schmidt, Thorsten: 1 article (09/2012)|
|5.||Buning, Christian: 1 article (09/2012)|
|6.||Kroll, Katja: 1 article (09/2012)|
|7.||Linz, Wolfgang: 1 article (09/2012)|
|8.||Ruf, Sven: 1 article (09/2012)|
|9.||Hübschle, Thomas: 1 article (09/2012)|
|10.||Linz, Dominik: 1 article (09/2012)|
|1.||Hypertension (High Blood Pressure)
01/01/2003 - "Further studies are underway to determine whether ebelactone B administration affects platelet activation events in experimental model of hypertension in rats."
09/15/1995 - "These results suggested that ebelactone B has promise as a preventive agent for the development of hypertension acting through the inhibition of urinary kinin degradation."
09/13/2012 - "Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension. "
10/15/1999 - "Daily administration of ebelactone B (EB), which is isolated from Actinomycetes and strongly inhibits CPY, from the first day of deoxycorticosterone acetate (DOCA)-salt treatment for 4 weeks completely blocked hypertension in Sprague-Dawley rats. "
01/01/1998 - "Daily oral administration of a selective inhibitor of CPY, ebelactone B, or that of NEP, BP1O2, prevented development of deoxycorticosterone acetate-salt hypertension in Sprague-Dawley rats. "
04/01/2005 - "We found that ebelactone B (5 mg/kg) administrated subcutaneously once a day for 5 days, 5 weeks after the development of hypertension, or a single dose of ebelactone B (0.5 mg/kg) injected intravenously into 2K1C hypertensive rats before the induction of arterial thrombosis, both markedly suppressed collagen-induced platelet aggregation in whole blood. "
01/01/2010 - "The previous treatment of spores with lipase activity inhibitor, ebelactone B, completely inhibited lipolytic activity, at all times specified, and prevented the infection of the R. "
01/01/2010 - "This work presents the activity profile during the host infection process and the effect of lipase activity inhibitor ebelactone B on infection. "
01/01/2010 - "The previous treatment of spores with lipase activity inhibitor, ebelactone B, completely inhibited lipolytic activity and prevented the infection of the Rhipicephalus (Boophilus) microplus host. "
01/01/2010 - "Here, we present the activity profile during the host infection process and the effect of lipase activity inhibitor ebelactone B on infection. "
|5.||Renovascular Hypertension (Goldblatt Syndrome)
04/01/2005 - "Thus, the data indicate that ebelactone B may be a promising antiaggregatory agent in renovascular hypertension and suggest that 1 of the possible mechanisms through which it exerts this effect may be related to the suppression of cathepsin A-like activity released locally during the development of renovascular hypertension."
|5.||Tissue Kallikreins (Tissue Kallikrein)
|9.||Lipase (Acid Lipase)
|10.||Dietary Fats (Ghee)